Platform for Controlled Human Malaria infection studies for development of new malaria vaccines, drugs and diagnostics in Africa (CHMI)

Objectives

To establish an African Controlled Human Malaria Infection (CHMI) platform in collaboration with established centres in the North, which will accelerate the development of new anti-malarial interventions and enable African researchers to play a key role in product development. The attainment of malaria elimination will require the development of new and better vaccines, diagnostics, drugs and systems. The malaria elimination and eradication agenda requires new approaches to transmission reduction. CHMI has been vital in the development of candidate malaria vaccines and offers a solution for rapid down selection of candidates for field studies.